Cogent Biosciences, Inc. (NASDAQ:COGT) Financings
Financings
| Raise | Date |
|---|---|
| At-the-market programme of shares Closed: US$73.6M raised Use of proceeds: Fund operating expenses and capital expenditures into late 2028, including through potential FDA approvals of bezuclastinib and early commercial launch | Aug 10, 2026 |
| 1.625% convertible senior notes due 2031 Update: US$200M · Jefferies +1 Dealers: Jefferies (co-lead), J.P. Morgan (co-lead) Use of proceeds: Repay $50 million of term loans; bezuclastinib development, regulatory work and commercial launch; other candidates; working capital and general purposes | Nov 11, 2025 |
| Public offering of shares of common stock Made bigger: US$200M · US$31 a share · J.P. Morgan +5 Dealers: J.P. Morgan (co-lead), Jefferies (co-lead), Leerink Partners (co-lead), Guggenheim Securities (co-lead), LifeSci Capital, Raymond James Use of proceeds: Repay $50 million of term loans; bezuclastinib development, regulatory work and commercial launch; other candidates; working capital and general purposes | Nov 11, 2025 |
| At-the-market programme of shares of common stock Closed: US$39M raised | Nov 3, 2025 |
| Public offering of shares of common stock Closed: US$230M raised · US$9 a share · J.P. Morgan +3 Dealers: J.P. Morgan (co-lead), Leerink Partners (co-lead), Guggenheim Securities (co-lead), LifeSci Capital Use of proceeds: Development, regulatory and commercial preparation for bezuclastinib and other candidates, its commercial launch, working capital and general corporate purposes | Jul 10, 2025 |
| At-the-market programme of common stock Closed: US$25M raised | Feb 25, 2025 |